Replies to post #10734 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

I think there’s a 72% probability that the FDA approves MNTA’s Copaxone ANDA before Teva’s patents expire in May 2014. (I don’t have a prediction for the next three months, as you requested.)

Regarding MYL’s ANDA, I have no insights other than to note that MYL acquired the product from India’s Natco, where approval standards for FoB’s are relatively low.